Micronized progesterone and estradiol combinations

Oral progesterone has roles alongside estrogen in menopausal therapy and in selected absence-of-periods conditions. The need for endometrial protection depends on the estrogen regimen and patient. Oral, vaginal and compounded topical preparations should not be assumed to provide the same exposure or protection. ¹

Bijuva is a defined oral combination for a specified menopausal indication. Its approval does not extend to every cream or capsule combining those hormones. The current 2026 label should guide discussion; older descriptions of its boxed warning may be obsolete. ²

Dizziness, drowsiness, breast tenderness and bleeding changes can occur with progesterone. Unexplained vaginal bleeding, clot history, hormone-sensitive cancer and liver disease should be discussed. Check inactive ingredients when there is a relevant allergy. The prescriber should explain what bleeding pattern warrants investigation. ^{1, 2}

When systemic estrogen is used by a person with a uterus, progesterone or another progestogen may be considered to reduce the risk of endometrial overgrowth. The needed regimen depends on the estrogen exposure and clinical situation; a topical cream should not be assumed to provide equivalent protection to an evaluated oral product. Unexplained bleeding needs assessment. Removing or changing progesterone independently can alter the safety of the complete hormone plan. ^{1, 2}

Oral micronized progesterone can cause dizziness and drowsiness, which is why the product-specific timing instructions matter. Capsules may contain peanut oil, so allergy history must be checked against the actual label and manufacturer. Discuss liver disease, clotting history, breast or reproductive cancers and unexplained vaginal bleeding. A compounded capsule, troche or cream can differ in excipients and absorption; identify the pharmacy, formulation and intended role rather than relying on the word micronized. ^{1, 2}

Review bleeding patterns, breast symptoms, sedation, mood, sleep and whether the original symptom target improved. The clinician should also confirm that estradiol and progesterone records reflect what is currently used, especially after a switch between separate products and a fixed combination. Seek urgent care for chest pain, sudden breathlessness, one-sided weakness, severe headache, vision change or painful leg swelling. New postmenopausal bleeding should be evaluated rather than managed by self-adjusting hormone doses. ^{1, 2}

Bedtime oral progesterone may cause drowsiness, and some patients report sleep changes, but sedation is not the same as treating a diagnosed sleep disorder. Review persistent insomnia, sleep apnea risk, mood symptoms and other sedating medicines separately. A compounded cream marketed for sleep may produce uncertain exposure and may not perform the endometrial role expected from a prescribed systemic regimen. ^{1, 2}